Table 39Fondaparinux vs UFH– Clinical summary of findings

OutcomeFondaparinuxUFHRelative riskAbsolute effectQuality
All cause mortality57/1103
(5.2%)
48/1110 (4.3%)1.2 (0.82, 1.74)9 more per 1000 (8 fewer to 32 more)LOW
VTE related mortality16/1103
(1.5%)
15/1110 (1.4%)1.07 (0.53, 2.16)1 more per 1000 (6 fewer to 16 more)LOW
Recurrent VTE rates (all patients)42/1103
(3.8%)
56/1110
(5.1%)
0.75 (0.51, 1.12)13 fewer per 1000 (25 fewer to 6 more)LOW
Subgroup: Cancer patients10/112
(8.9%)
22/128
(17.2%)
0.52 (0.26, 1.05)83 fewer per 1000 (127 fewer to 9 more)LOW
Major bleeding (all patients)22/1103
(2%)
26/1110
(2.3%)
0.85 (0.49, 1.49)4 fewer per 1000 (12 fewer to 11 more)LOW
Subgroup: Cancer patients2/112
(1.8%)
3/128
(2.3%)
0.76 (0.13, 4.48)6 fewer per 1000 (20 fewer to 82 more)LOW
Fatal bleeding3/1103
(0.3%)
1/1110
(0.1%)
3.02 (0.31, 28.98)2 more per 1000 (1 fewer to 25 more)VERY LOW

From: 7, Pharmacological interventions

Cover of Venous Thromboembolic Diseases
Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing [Internet].
NICE Clinical Guidelines, No. 144.
National Clinical Guideline Centre (UK).
Copyright © 2012, National Clinical Guideline Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.